Silexion TherapeuticsSLXN
13F holders, Q1 2025 (March 31)5holders +2
3new positions
1sold out
$1.10avg. 13F price*
At the end of Q1 2025, 5 institutions reported holding Silexion Therapeutics Corp. (SLXN) in their 13F filings, up 2 from Q4 2024. 3 opened new positions and 1 sold out. The largest holders were Wildcat Capital Management, LLC ($125K), UBS Group AG ($80K) and Meyer Handelman Co. ($36K).
- Company
- Silexion Therapeutics Corp.
- CUSIP
- G1281K122
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $55K |
| Exits | 1 | $23K |
All 13F filers, Q4 2024 → Q1 2025: 107,898 shares bought and 11,887 shares sold, net +96,011 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Wildcat Capital Management, LLC | 0.07% | No change | 113,428 | $125K |
| UBS Group AG | 0.00% | Add +390.6% | 72,874 | $80K |
| Meyer Handelman Co. | 0.00% | New | 32,967 | $36K |
| SBI Securities Co., Ltd. | 0.00% | New | 16,411 | $18K |
| Bank of America Corp. | 0.00% | New | 500 | $550 |
"% of holder's portfolio" is SLXN's weight in each manager's 13F, not the share of Silexion Therapeutics Corp. the manager owns.